TMC Life Sciences BhdXKLS:0101 +1.09%60 Return-on-Tangible-Equity is 1.06% as of Mar. 2026, which is 78% below its 10-year median of 4.85. GuruFocus rates XKLS:0101 with a GF Score™ of 60/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 580 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks worse than 68.97% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. TMC Life Sciences Bhd's annualized net income for the quarter that ended in Mar. 2026 was RM7.0 Mil. TMC Life Sciences Bhd's average shareholder tangible equity for the quarter that ended in Mar. 2026 was RM664.0 Mil. Therefore, TMC Life Sciences Bhd's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 1.06%.
The historical rank and industry rank for TMC Life Sciences Bhd's Return-on-Tangible-Equity or its related term are showing as below:
XKLS:0101'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.54 Med: 4.85 Max: 6.74
Current: 2.31
During the past 13 years, TMC Life Sciences Bhd's highest Return-on-Tangible-Equity was 6.74%. The lowest was 0.54%. And the median was 4.85%.
XKLS:0101's Return-on-Tangible-Equity is ranked worse than 68.97% of 580
companies
in the Healthcare Providers & Services industry
Industry Median: 10.065
vs XKLS:0101: 2.31
TMC Life Sciences Bhd (XKLS:0101) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
TMC Life Sciences Bhd Return-on-Tangible-Equity Related Terms
TMC Life Sciences Bhd Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for TMC Life Sciences Bhd's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd Return-on-Tangible-Equity Chart
XKLS:0101 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.06% mean?
TMC Life Sciences Bhd (XKLS:0101) has a Return-on-Tangible-Equity of 1.06% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TMC Life Sciences Bhd and its competitors. This is 78% below median its historical median of 4.85. Over the past decade, TMC Life Sciences Bhd's Return-on-Tangible-Equity has ranged from 0.54 to 6.74. According to the industry distribution chart, TMC Life Sciences Bhd ranks #400 out of 580 companies in the Healthcare Providers & Services industry, placing it in the top 69%.
Is TMC Life Sciences Bhd's Return-on-Tangible-Equity too high?
TMC Life Sciences Bhd's current Return-on-Tangible-Equity of 1.06% is 78% below median its 10-year median of 4.85. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 6.74. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.07. TMC Life Sciences Bhd's value of 1.06% is 89.5% below this industry median. Based on the distribution chart, TMC Life Sciences Bhd ranks #400 out of 580 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, TMC Life Sciences Bhd has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #400 out of 580 companies for Return-on-Tangible-Equity. This places TMC Life Sciences Bhd in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.07. TMC Life Sciences Bhd's value of 1.06% is 89.5% below this benchmark. Historically, TMC Life Sciences Bhd's own Return-on-Tangible-Equity has ranged from 0.54 to 6.74 over the past decade. While the company's 10-year median is 4.85 vs. the industry median of 10.07, TMC Life Sciences Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.07, based on 580 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TMC Life Sciences Bhd's current Return-on-Tangible-Equity of 1.06% is 89.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current Return-on-Tangible-Equity is 1.06%, which is 78% below median its own 10-year median of 4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.47 — trading 25% below its estimated fair value. The current Return-on-Tangible-Equity is 1.06%, which is 78% below median its 10-year median of 4.85 and 89.5% below the Healthcare Providers & Services industry median of 10.07. TMC Life Sciences Bhd's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current Return-on-Tangible-Equity is 1.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.47 is trading 25% below its estimated GF Value™ of RM0.62.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
Return-on-Tangible-Equity: 1.06% (78% below median its 10-year median of 4.85)
GF Value™: RM0.62 vs. price of RM0.47 (25% below fair value)
Industry Position: 89.5% below the Healthcare Providers & Services median (#400 of 580)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
60GF Score
Get the complete analysis for XKLS:0101
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
